The UK’s National Institute of Health and Care Excellence (NICE) said the drug provided only a small benefit to patients.

There have been many promising leads for an Alzheimer's vaccine but new treatments have been slow to merge. Researchers at ...

Donanemab, the most effective treatment yet for the disease, has been banned on the health service despite regulators ...

The National Institute for Health and Care Excellence (Nice) confirmed on Wednesday that it would not fund donanemab - the ...

It marks the second such rejection in the UK for an Alzheimer’s treatment, after Eisai and Biogen’s drug met the same fate ...

The approval marks the second Alzheimer's drug facing a split decision in a short span. Despite the Medicines and Healthcare products Regulatory Agency's endorsement of Kisunla, also known as ...

Eli Lilly's donanemab receives UK approval for mild cognitive impairment and mild dementia due to Alzheimer's disease.

Donanemab marks a significant advancement in Alzheimer’s treatment, but NHS patients face a setback with NICE's rejection of ...

Eli Lilly’s Alzheimer’s disease offering Kinsunla is poised to face a tough road ahead in the U.K. | Lilly's Alzheimer ...

A wife whose husband will not be eligible for new Alzheimer’s drugs has implored health leaders to ensure that others like ...

The UK’s healthcare spending watchdog has rejected Eli Lilly’s (LLY) Alzheimer’s drug as being too expensive despite being ...

Eli Lilly (LLY) announced that the Medicines and Healthcare products Regulatory Agency, or MHRA, has granted marketing authorization for ...